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The intent of this research is to assess the enzyme diaminopimelate aminotransferase 
(DapL), an enzyme involved in the biosynthetic pathway of the essential amino acid 
L-lysine. Enzymes involved in L-lysine biosynthesis represent a valuable model for 
the elucidation of potential therapeutic targets, as animals cannot synthesise L-lysine 
de novo and require it through the diet. Recently, it has been found that all bacteria in 
the genus Chlamydia, including Chlamydia trachomatis the causative agent in 
sexually transmitted infection chlamydia, use the DapL enzyme to syntheise L-lysine. 
The closest free living relative to C. trachomatis, Verrucomicrobium spinosum is not 
pathogenic and has the unique feature of exclusively using DapL to synthesise L-
lysine. V. spinosum is therefore a model organism for assessing the viability of DapL 
enzymes as therapeutic targets. 
 
In this work, DapL from V. spinosum (VsDapL) was successfully expressed and 
purified before elucidating any kinetic, structural and biophysical properties of the 
enzyme.  Analysis of the biophysical properties of VsDapL indicates that the enzyme 
exists in a monomer-dimer equilibrium in solution, however is predominantly dimeric 
at higher concentrations. This feature has never been reported in DapL orthologues. 
Finally, the first reported crystal structure for VsDapL using X-ray crystallography is 
presented and confirms the dimeric structure at higher concentrations found in the 
biophysical experiments. Comparison of the VsDapL structure with previously 
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This thesis describes the first biophysical and structural characterisation of the 
enzyme diaminopimelate aminotransferase (DapL) from the bacteria 
Verrucomicrobium spinosum. DapL is the most recently identified enzyme in the 
lysine biosynthetic pathway and catalyses one of four alternative routes towards the 
synthesis of lysine. Various experimental approaches were employed in order to 
characterise DapL including analytical ultracentrifugation (AUC), X-ray 






In nature, only nine out of the twenty known proteinogenic amino acids are 
considered to be essential for animals. Essential amino acids are nutritionally 
necessary, meaning they cannot be synthesised by mammalian enzymes de novo and 
therefore have to be ingested through the diet 1. The aspartatic-derived amino acids, 
L-isoleucine (Ile, I) L-lysine (Lys, K), L-methionine (Met, M) and L-threonine (Thr, 
T) comprise four of the nine essential amino acids. 
 
The biosynthesis of one particular aspartatic-derived amino acid, L-lysine (Figure 
1.1), has recently been of high interest due to its nutritional importance in the diet and 











1.1:  The chemical scaffold of L-lysine. L-lysine is comprised from six straight chain carbons with a 
terminal primary amine group (NH2). The amine moiety enables contributes to its overall activity in 
several important physiological reactions. Constructed in CHEMDRAW. 
 
The current understanding of the biosynthetic pathway of L-lysine stems from the 
identification of one of its precursor molecules meso-diaminopimelate (meso-Dap), in 
1950 3, 4. Following the identification of meso-Dap, the development of narrow-
spectrum antibiotics and herbicides that target enzymes within the L-lysine pathway 
has expanded, due to the low mammalian toxicity they possess 5, 6. Narrow-spectrum 
antibiotics only target potential pathogens, while broad-spectrum antibiotics affect 
both potential pathogens and also the naturally occurring flora 7. Availability of novel 
narrow-spectrum antibacterial agents that only affect a distinct group of bacterial 
species lowers the risks of disrupting the naturally occurring micro-biome, due to the 
potential detrimental effect on organisms involved in important physiological 
processes 8.  
 
L-lysine and meso-Dap are possible targets of antibacterial agents, as most gram-
negative and gram-positive bacteria require both to form a major structural 
component of the cell wall, peptidoglycan 9-12. Peptidoglycan is a polymer that has an 
alternating disaccharide backbone of N-acetyl-glucosamine (NAG) and N-acetyl-
muramic (NAM) acid, cross-linked by peptide chains 13. Cross-linking of the 
backbone occurs via the amide functionality of L-lysine or meso-Dap and position 
four of a second side chain 14. The importance of peptidoglycan in the structure of cell 
wall has presented a crucial target for the development of several therapeutic 
compounds including β-lactams and glycopeptides 11, 15. As mammals cannot 
synthesize L-lysine, enzymes within the biosynthetic pathway represent a valuable 






1.3 L-lysine biosynthetic pathways  
 
1.3.1  Overview of L-lysine biosynthetic pathways  
 
Two different pathways have evolved to synthesize L-lysine. L-lysine is either 
synthesised from 2-oxoglutarate and acetyl-CoA using the α-aminoadipate pathway 
(AAA), or from aspartate using the diaminopimelate (Dap) pathway. Fungi and 
euglena employ the AAA pathway, while archaea, bacteria and plants employ the 
diaminopimelate Dap pathway 20.  The two pathways are separated by a significant 
evolutionary gap suggesting that they developed separately in organisms that were 
unable to synthesize lysine 21. 
 
1.3.2 The α-Aminoadipate (AAA) pathway  
 
The existence of the AAA pathway for lysine biosynthesis has been established in 
several yeasts, fungi and euglena however the majority of the biochemical and genetic 
understanding of this pathway results from studies with the yeast Saccharomyces 
cerevisiae 22, 23. The precursor molecule within the AAA pathway is 2-oxoglutarate, a 
key intermediate in the citric acid cycle. L-lysine is constructed of four carbons 
derived from 2-oxoglutarate and two carbons derived from acetate 21.  Despite the 
lack of knowledge surrounding the AAA pathway due to the pathway only being 
present in yeasts, euglena and higher fungi, two routes have been established (Figure 
1.2) 24. The action of two gene products is required in a few reactions that involve 









Figure 1.2: The AAA Pathway with all known substrates and enzymes. Figure taken from 26 and 





1.3.3  The diaminopimelate (Dap) pathway 
 
The Dap pathway was first described in the bacteria Escherichia coli and is named 
after the characteristic intermediate, L,L-2, 6-diaminopimelic acid (L,L-Dap) 4, 12, 21, 
27. The carbon skeleton of L-lysine is constructed from carbons originating from L-
aspartate and pyruvate as opposed to 2-oxoglutarate and acetate in the AAA pathway 
12. The enzymes and intermediates vary significantly from the AAA pathway, as the 
precursor molecule is L-aspartate, rather than 2-oxoglutarate. The three other aspartic-
derived essential amino acids, Met, Thr and Ile are also formed through a branched 
segment of the Dap pathway and thus there have been several recent studies that have 
allowed for a better understanding 28. 
 
The Dap pathway proceeds via up to nine enzymatic steps, each with a precursor 
substrate and specific enzyme (Figure 1.3). The pathway is divided into two sections, 
the upper section (reactions 1-4) that is common for all variants of the Dap pathway, 






Figure 1.3: The Dap Pathway with all substrates enzymes. The four sub-pathways, the succinylase, 
acetylase, dehydrogenase and aminotransferase pathways of the L-lysine pathway are shown. The 





1.3.4  The upper dap pathway 
 
The first reaction in the Dap pathway is catalysed by the enzyme aspartate kinase 
(LysC, EC 2.7.2.4) and yields L-aspartyl-phosphate from L-aspartate with the input of 
metabolic energy in the form of ATP. The second reaction is catalysed by the enzyme 
aspartate semialdehyde dehydrogenase (AspD, EC 1.2.1.11) and takes the high-
energy species L-aspartyl-phosphate and forms L-aspartate-semialdehyde 28. These 
first two steps catalyse the synthesis of intermediate molecules that are common 
precursors for the formation of L-lysine, but also for the three other essential aspartic-
derived amino acids, Thr, Met and Ile.  
 
The key intermediate, L-tetrahydrodipicolinate (THDP), is formed via the third and 
fourth reactions in the pathway, and proceeds through the reaction of L-aspartate 
semialdehyde with pyruvate, followed by further reaction with the high-energy 
molecule NADPH. Dihydrodipicolinate synthase (DHDPS, EC 4.3.3.7) encoded by 
the DapA gene and dihydrodipicolinate reductase (DHDPR, EC 1.17.1.8) encoded by 
the DapB gene catalyse these two reactions. DHDPS catalyses the first committed 
step in the lysine biosynthetic pathway, where the substrates L-aspartate-
semialdehyde and pyruvate are condensed to form an unstable heterocycle HTPA 31. 
This highly unstable product is a substrate for DHDPR in a pyridine nucleotide-
dependent reduction of dihydrodipicolinic acid (DHP) that generates the product 
THDP 32. Recent characterisation has found that bacterial and plant DHDPR exists in 
two different oligomeric states, suggesting complexity in the pathway between 
species 33, 34. The cyclic intermediate THDP generated by DHDPR in the fourth 
reaction, can be reversibly hydrolysed to its open chain form L-α-amino-ε-keto-












Figure 1.4: The reversible hydrolysis reaction of tetrahydrodipicolinate and L-α-amino-ε-keto-
pimelate. The cyclic form (left) has the nitrogen moiety tied up in a 6 membered ring structure while 
the open acyclic form (right) has the nitrogen moiety exposed as a protonated amine (NH3+) at 
physiologic pH values. Both forms are recognised at further stages in the reaction. 
 
1.3.5  The lower dap pathway 
 
Following the formation of THDP, subsequent reactions of the Dap pathway can vary 
depending on the branch of the pathway taken, however, all branches form the 
intermediate meso-Dap due to it being the immediate precursor molecule for PG and 
therefore crucial for cell wall synthesis 35. There have been four known sub-pathways 
from the intermediate THDP to form meso-Dap that have been described within 
archaea bacteria and plants (Figure 1.3) 36. Two of these pathways, the succinylase 
and acetylase pathways, have been identified to be the major routes taken by gram 
positive and negative bacteria, where multiple N-succinylated or N-acetylated 
intermediates are formed 37.  
 
However, two other pathways, the aminotransferase pathway catalysed by the enzyme 
diaminopimelate aminotransferase (DapL, EC 2.6.1.83) and the dehydrogenase 
pathway catalysed by the enzyme diaminopimelate dehydrogenase (DapDdh, EC 
1.4.1.16), have been identified however are less frequently used 38. It was previously 
believed that only one of the four pathways is active at a given time, however, recent 
research with the bacteria Corynebacterium glutamicum has suggested that pathways 
can be active at the same time to handle a potential increase in flow of metabolites 
entering the pathway 39, 40. The succinylase and acetylase pathways are analogous to 
each other and require several steps using multiple enzymes to form L,L-Dap, while 
the aminotransferase route only requires one step 36. Preferentially using the pathways 
that require multiple enzymes and steps, over the one-step pathway, demonstrates the 





The dehydrogenase pathway variation mediates a similar conversion however forms 
meso-Dap rather than L,L-Dap in one step 41. If the dehydrogenase pathway is not 
active then meso-Dap is synthesised through isomerisation of L,L-Dap by the enzyme 
diaminopimelate epimerase (DapF, EC 5.1.1.7) 42. In bacteria, meso-Dap is either 
incorporated into the PG or it is decarboxylated via the enzyme meso-
diaminopimelate decarboxylase (LysA, EC 4.1.1.20) to the final product of the 
pathway L-lysine 30. If the later is the case, meso-Dap is stereospecifically 
decarboxylated at the D centre with inversion of configuration. 
 
1.3.6  The aminotransferase pathway 
 
The aminotransferase pathway catalysed by DapL was only recently uncovered 
through extensive genomic analysis in the plant Arabidopsis thaliana in 2006 by 
Hudson et al. 30. DapL catalyses the reversible transamination of THDP to L,L-Dap in 
one-step and therefore bypasses the use of multiple enzymes (Figure 1.5). The 
reaction proceeds through a bimolecular ping-pong mechanism and acts to transfer the 
amino group from the L-glutamate, which acts as an amino donor to the product L,L-






Figure 1.5: The reversible chemical reaction of THDP to L,L-Dap catalysed by DapL. L-
glutamate acts as the amino donor in the reaction and is converted to α-ketoglutarate. The cofactor 
pyridoxal-5-phosphate (PLP) is used as an amino acceptor in the reaction. 
	
Identification of DapL in plants prompted investigation within bacteria, and has since 
only been found in 13% of all bacterial genomes (calculated from genome annotation 
in the Integrated Microbial Genomes database) 8, 43. Thus the majority of bacteria 
employ alternative variants of the Dap pathway to synthesise PG and L-lysine. 
Interestingly, the genera Chlamydia, the causative agent in the sexually transmitted 
infection chlamydia, Leptospira, the cause of the kidney disease leptospirosis, and 
Treponema the principal cause of the sexually transmitted infection syphilis, all use 
the aminotransferase pathway to synthesise L-lysine 8. Thus any potential inhibitor of 
DapL could have vast potential as a narrow-spectrum antibiotic target in bacteria that 
use the pathway.  
 
1.4  Crystal structures of DapL 
 
Phylogenetic analysis of DapL enzymes indicated that two classes of DapL existed 
based on sequence similarity, type I and type II 43, 44.  Type I DapL is common among 
plants and chlamydia while type II are more common in bacteria 44. Crystal structure 





Chlamydomonas reinhardtii and Chlamydia trachomatis (Figure 1.6). Comparison of 
the crystal structures has provided insight into structural differences that occur 
between orthologues and have aided in the search potential for therapeutic targets. 
 
 
Figure 1.6: The dimeric crystal structure of DapL. Left to right: A. thaliana, C. reinhardtii and C. 
trachomatis DapL. The two monomers are labeled A and B and are separated based on colour. Images 
were generated using Pymol 45. 
 
 
1.4.1 Arabidopsis thaliana DapL 
 
After the initial discovery of the aminotransferase pathway in the plant A. thaliana, 
the structure of DapL was solved to 1.95 Å by Watanabe et al. 2007 and was used as a 
foundation for further work for other organisms that employ the aminotransferase 
pathway 46, 47. It was found that DapL from A. thaliana (AtDapL) exists as a 
homodimer in both the apo- form and with a cofactor pyridoxal-5-phosphate (PLP), a 
feature shared by many aminotransferase enzymes (Figure 6). The enzyme contains 
two active sites, comprised from residues from both monomers indicating that a 
dimeric structure must be adopted to be active. The overall structure of the fold of 
AtDapL closely resembles that of type I aminotransferases, indicating that structure is 
conserved within PLP dependent enzymes 46. 
 
1.4.2 Chlamydomonas reinhardtii DapL 
 
Stemming from the research with AtDapL, the crystal structure of DapL from the 
unicellular alga C. reinhardtii (CrDapL) was solved to 1.55 Å by Dobson et al. 2011, 





structure for CrDapL in its apo- form displayed a similar homodimer characteristic of 
A. thaliana and was classified as a type I aminotransferase 48 . 
 
1.4.3 Chlamydia trachomatis DapL 
 
Recent research has identified that all bacteria in the genera Chlamydia employ the 
aminotransferase pathway in biosynthetic pathway of L-lysine to synthesise 
peptidoglycan 30. The bacterium C. trachomatis is one of four species in the 
Chlamydiae genus and is most commonly associated with being the cause of the most 
frequently reported sexually transmitted infection (STI) known as chlamydia 49. C. 
trachomatis has also been well documented in several severe human diseases 
including trachoma, the leading cause of preventable blindness 50.  
 
The crystal structure of DapL from C trachomatis (CtDapL) is the most recent DapL 
structure published and was solved to 2.05 Å by Watanabe et al. 2011, in both its apo- 
form and additionally with the co-factor PLP 51. CtDapL was found to adopt a 
homodimer oligomeric state in line with type I aminotransferases. However despite C. 
trachomatis DapL sharing over 40% sequence identity and with AtDapL, substrate 
specificity differed significantly between the two organisms. CtDapL displayed 
promiscuous substrate specificity in comparison to AtDapL is suggested to be due to 
several flexible residues that comprise the pocket of the active sites that differ 
between organisms 44. This feature of substrate specificity still remains unclear, 
however further structural studies in different organisms may provide some insight 
into this feature.  
 
1.5  Research goals and perspective of this thesis 
 
While mammals cannot synthesise L-lysine in vivo and acquire it through the diet, 
many organisms including bacteria, plants, and archaea can synthesise it via the AAA 
and Dap pathways outlined above. The work presented in this thesis focuses on the 
first structural and biophysical characterisation of DapL from the bacterium 






V. spinosum is a free-living, non-pathogenic bacterium, closely related to C. 
trachomatis, however it bears the specific feature of only synthesising meso-Dap and 
L-lysine through the aminotransferase pathway using the enzyme DapL 30, 52-54. V. 
spinsosum is not pathogenic and the feature of solely employing the aminotransferase 
pathway for L-lysine biosynthesis allows it to be used as a model organism in which 
DapL enzymes from pathogenic organisms can studied in. This may aid the 
development of antibacterial, herbicidal or algaecidal compounds 8.  
 
The structural elucidation of V. spinosum DapL (VsDapL) for therapeutic discovery 
was the principal focus of this thesis, however the work performed also aids in 
assessing whether DapL is a feasible target for compounds in all human pathogenic 
bacteria that use the aminotransferase pathway.  
  
Chapter 2 of this thesis discusses the specific protocol and results for the successful 
expression and purification of DapL from V. spinosum.  
 
Chapter 3 entails the kinetic assays and analysis of VsDapL using steady-state initial 
rate kinetic experiments with and also without inhibitors.  
 
Chapter 4 explores the biophysical properties of VsDapL in solution using the 
techniques circular dichroism (CD), analytical ultracentrifugation (AUC) and small 
angle X-ray scattering (SAXS).  
 
Chapter 5 describes in detail the first X-ray crystallography structure of VsDapL and 
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Chapter Two – Expression and Purification of DapL from 
Verrucomicrobium spinosum 
 
2.1  Introduction 
 
Due to the potential benefits of targeting the biosynthetic pathway of L-lysine 
for antibiotic drug discovery, a considerable amount of research has been directed 
towards understanding the enzymes involved in the diaminopimelate (Dap) pathway. 
The aminotransferase enzyme involved in the Dap pathway (DapL) has previously 
been characterised in three different organisms, however it has never been 
characterised from the bacteria Verrucomicrobium spinosum 1-4. V. spinosum has the 
unique feature of only using the aminotransferase pathway to synthesise L-lysine and 
its precursor meso-Dap, therefore it can be used as a model organism in the 
development of potential antibacterial, herbicidal or algaecidal compounds 5. 
Expression and purification of the DapL protein from V. spinosum (VsDapL), was 
required to understand its structural, biophysical and kinetic properties discussed in 
later chapters. 
 
The work in this chapter includes the successful expression and purification of 
VsDapL, using Escherichia coli in BL21*(DE3) cells. The pET30a(+) plasmid 
containing the His-Tagged VsDapL gene was generously provided by Associate 
Professor André Hudson of Rochester Institute of Technology. Previously reported 
methods of expression and purification were adapted here for the best expression of 
VsDapL. 
  
2.2  Transformation and over-expression of VsDapL 
 
Escherichia coli expression strains are the favored bacterial expression system for 
heterologous gene expression due to the significant advantages including the feature 
of quick growth, simplicity and low cost 6, 7.  In this work, the BL21*(DE3) 





T7 expression strain that has a mutation in the RNAseE gene, resulting in a greater 
transcript half-life 8. The pET30a(+) plasmid containing the His-Tagged VsDapL gene 
was transformed into BL21*(DE3) expression cells. Transformed colonies formed 
overnight on kanamycin containing agar pates and were used for expression. 
Previously reported methods were trialed via small-scale expression allowing the best 
conditions for VsDapL to be established. The expression method that was found to be 
the best for over-expression of VsDapL followed the protocol detailed in Chapter 6, 
section 6.3.7 and was used in all expression work throughout this thesis. Cells were 
harvested following protein expression via centrifugation and either frozen at -20°C 
for future use, or resuspended in appropriate buffer ready for lysis. 
 
2.3 Cell lysis 
 
There are several practices to lyse bacterial cells, however throughout this work cells 
were lysed using sonication via an ultrasonic probe. Sonication involves the shearing 
of cells by the immersion of a probe into the desired solution and emitting ultrasonic 
high frequency sound waves in pulses 9. The cells were resuspended in appropriate 
buffer and were sheared open via sonication. In order to achieve maximum cell 
shearing, while limiting the denaturing of a protein, the temperature of the solution 
and time intervals between sonication was carefully monitored as heat is liberated in 
the process 10. Shearing of the cells released the proteins within the cell into the 
suspension where it was then centrifuged to separate insoluble and soluble protein. 
Soluble proteins remained in the supernatant, while the insoluble proteins and other 
aggregates formed a pellet. The supernatant (or crude lysate) containing soluble 
VsDapL was carefully collected and kept on ice or at 4°C ready for purification and 
the pellet was discarded. 
 
2.4 Immobilised metal affinity chromatography (IMAC) 
 
Following collection of the crude lysate, VsDapL was purified by means of 
immobilised metal affinity chromatography (IMAC), whereby a polyhistidine tag on 





containing His-tagged VsDapL was loaded onto the IMAC column, washed with 
buffer containing low imidazole to remove any nonspecific binding, and then eluted 
with buffer containing high imidazole. Purity of VsDapL was assessed using SDS-
PAGE (Figure 2.1). 
 
 
Figure 2.1:  SDS-PAGE following the IMAC His-Trap Purification of VsDapL:. Lanes 1: Protein 
Standard (Top to bottom (kDa): 160, 110, 80, 60, 50, 40 30, 20,15 and 10) Lanes 2-13 – eluted 
fractions 
 
Comassie brilliant blue staining of the gel displayed a single band at approximately 45 
kDa which is in agreement with the calculated molecular weight of VsDapL as a 
monomer at 44.7 kDa, calculated from the amino acid sequence using exPASy 
ProtParam and beer’s law 12. The fractions containing VsDapL were pooled and 
concentrated to a volume of 1.5 mL for further purification. 
 
2.5 Size exclusion chromatography 
 
Size exclusion chromatography (SEC) was used as a second purification step to 
separate proteins that may have co-eluted with VsDapL in the IMAC purification step. 
Separation using SEC is based on the size of the molecule, as smaller molecules pass 
through a column containing specifically shaped small pores slower than larger 





were loaded onto a pre-equilibrated column and eluted over 120 minutes with desired 
buffer. Fractions were collected in 1 mL aliquots and purity of the VsDapL was 
assessed using SDS-PAGE (figure 2.2). Comassie brilliant blue staining of the gel 




Figure 2.2: SEC purification of VsDapL (a) An SDS-PAGE gel of collected fractions within the peak 
following SEC. Lane 1: Protein Standard (Top to bottom (kDa): 160, 110, 80, 60, 50, 40 30, 20,15 and 
10), Lanes 2-9: fractions from the peak displayed by SEC chromatogram (b) SEC chromatogram 
displaying the elution of VsDapL. 
 
Samples from each step of the purification were run on SDS-PAGE to track a typical 
purification of VsDapL (figure 2.3). The protein became more pure with each 
purification step. The band at 44.7 kDa, indicative of the monomeric molecular 
weight of VsDapL, becomes increasingly visible with less contamination following 
IMAC and SEC purification methods, however SEC was run in all purifications to 
remove any impurities that may have been present following IMAC. The 
concentration of the purified VsDapL was calculated using a Nanodrop 
spectrophotometer or by the Bradford assay Pure protein was then pipetted into 
different volumes and concentration aliquots, snap frozen in liquid nitrogen and 








Figure 2.3:  SDS-PAGE showing the purification process of VsDapL. Lane 1: Protein Standard 
(Top to bottom (kDa): 110, 80, 60, 50, 40 30, 20,15 and 10), Lane 2, Crude lysate; Lane 3, Soluble 
protein (centrifuged lysate); Lane 4, IMAC flow through; Lane 5, Post IMAC; Lane 6, Post SEC. 
 
 
Table 2.1 Purification table of a typical VsDapL purification 
 Starting 
Volume 






VsDapL  2 L ~50 mL 
 
1.5 mL at 35 
mg/mL 





In order to assess the biophysical, structural and kinetic properties, successful 
expression and purification of the VsDapL was required.  This chapter describes the 
transformation of VsDapL into E. coli BL21*(DE3) cells, followed by the successful 
over-expression and purification via a two-step purification process with the use of 
IMAC and size exclusion chromatography. SDS Page gel electrophoresis was used to 
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Chapter Three - Kinetic Analysis of VsDapL 
 
3.1  Introduction 
 
As outlined in chapter one chapter 1, the diaminopimelate (Dap) pathway provides an 
alternative route to L-lysine, as it catalyses a reaction that bypasses several enzymatic 
steps. Previously reported catalytic mechanisms for pyridoxal-5-phosphate (PLP) 
dependent aminotransferase enzymes show that the reaction follows the bimolecular 
ping-pong mechanism and is, of course, reversible (Figure 3.1) 1, 2. 
 
Figure 3.1: The general mechanism scheme of ping-pong bimolecular reactions. E = enzyme , A= 
substrate 1 , EA enzyme substrate 1 complex, E*P= modified enzyme product complex, E* = modified 
enzyme, E*B enzyme substrate 2 complex, E*Q = modified enzyme product 2 complex, Q = Product 
2.  
 
In the transaminase reaction, an amino-group is transferred from an amino donor 
(usually an amino acid) to its corresponding α-keto acid, which acts as an amino 
acceptor 3. A general schematic of the role of PLP in a typical aminotransferase 
reaction mechanism is shown below in Figure 3.2. The mechanism proceeds through 
the formation of a Schiff base, whereby PLP acts as a co-enzyme and is tethered to a 
lysine side chain located within the active site of the enzyme 4, 5. This allows the 
amine group to be donated onto the keto- moiety of the amino acceptor to form it’s 


















3.2  The aminobenzaldehyde assay 
 
The aminobenzaldehyde assay has previously been developed to collect initial rate 
data of PLP-dependent aminotransferase enzymes. It measures the initial rate of the 
reaction, whereby a change in concentration of either substrate or product is measured 
as a function of time 8. A variation of the aminobenzaldehyde assay, the coupled 
ortho-aminobenzaldehyde assay developed by Hudson et al. 2006 9, measures the 
production of a dihydroquinazolium adduct at 440 nanometers (nm) and has been 
reported in several diaminopimelate aminotransferase (DapL) kinetic studies 10-13. In 
this work, the catalytic activity of Verrucomicrobium spinosum DapL (VsDapL) was 
measured using this assay in the reverse direction (Figure 3.3).  
 
The forward (anabolic) reaction proceeds via the donation of an amine group from L-
glutamate to tetrahydrodipicolinate acid (THDP), while in the reverse (catabolic) 
reaction the amine group from L,L-diaminopimelate is donated onto α-ketoglutarate 
(α-KG) 14. o-Aminobenzaldehyde reacts with THDP and generates a yellow tinted 
dihydroquinazolium adduct that absorbs light at 440 nm. The activity of the o-
aminobenzaldehyde assay has been noted to proceed significantly faster via the 
reverse direction with respect to the kinetic parameter Vmax 10. The side reaction that 
may occur between α-ketoglutarate and o-aminobenzaldehyde has been shown to be 
so poor that it can be considered negligible, thus this coupled assay provides a simple 







Figure 3.3:  The chemical reaction scheme of the variation of o-aminobenzaldehyde Assay. The 
formation of THDP is coupled to the formation of a dihydroquinazolium adduct that absorbs at 440 






3.3  VsDapL o-aminobenzaldehyde assay  
 
The reverse o-aminobenzaldehyde was used to extrapolate kinetic parameters of 
VsDapL. The assay showed that VsDapL is a reasonably inefficient enzyme with 
respect to the substrate L,L Dap. The apparent values for KM (4.1 mM) and Vmax (0.52 
mM/s-1) are consistent with those previously reported in the literature (Table 3.1). 
However, the catalytic turnover rate of 7.7 s-1 and the catalytic efficiency 1.9 x 103 s-
1M-1 measured for VsDapL are slightly higher than previously reported values but are 
still notably lower than other reported DapL orthologues 16.  
 
 
Figure 3.4:  Kinetic plot showing the activity of VsDapL against varying concentrations of 
substrate (L,L-Dap) at pH 7.0. A Michaelis-Menten curve was fitted to find the kinetic parameters 
Km and Vmax. Data was fitted using Prism 6 
 
Table 3.1: Kinetic parameters for the o-aminobenzaldehyde assay with VsDapL. Previously 
reported constants for VsDapL* and CrDapL are compared. 
 VsDapL VsDapL* CrDapL 
KM for L,L Dap (mM) 4.003 ± 0.4 4.1± 1 2.7± 0.7 
kcat (s-1) 
kcat / Km (s-1M-1) 
7.719 
1.9 x 103 
1.6 
0.4 x 103 
16.4 





3.4 VsDapL ortho-aminobenzaldehyde inhibition assay 
 
As DapL orthologues have potential to be used in the development of antibacterial, 
herbicide or algaecide compounds, a number of inhibitors have been screened with 
the enzyme 14, 16. The inhibitors identified in the initial screens (malic/maleic acid) 
were required in elucidating the crystal structure of VsDapL (Chapter five); therefore 
it was logical to attempt to determine catalytic properties of VsDapL in the presence 
of these inhibitors.  
 
Three models of inhibition (competitive, mixed and non-competitive) were fitted to 
the inhibition assay experimental data. When modeled, the data did not fit any of the 





Figure 3.5:  Kinetic plot showing the activity of VsDapL against varying concentrations of 
substrate (L,L-Dap) with varying concentrations of inhibitor (Malic acid) present at pH 7.0. A 






A Lineweaver-Burk plot was generated to determine the model that best describes the 
experimental data (Figure 3.6). If the data were to fit a competitive inhibition model 
then only the KM would increase as the inhibitor concentration increased while Vmax 
would remain the same. In the noncompetitive model, the Vmax would increase as the 
concentration of inhibitor increased, while KM remains constant. From the 
experimental data, it can be seen that both Vmax and KM are clearly altered by an 
increase in inhibitor concentration and therefore the mixed inhibition model was 
fitted. The apparent inhibition constant (KI) of 48.7 µM was calculated from the 
mixed-inhibition model. R-square values given from each model were also compared 





Figure 3.6:  A Lineweaver-Burk plot showing the activity of VsDapL against varying 
concentrations of substrate (L,L-Dap) with varying concentrations of inhibitor (Malic acid) 
present at pH 7.0. A mixed-model inhibition fit was modeled to the experimental data and graphed 









The reverse coupled o-aminobenzaldehyde was used to extrapolate kinetic parameters 
of VsDapL. The apparent values for the KM of 4.1 mM and Vmax 0.52 mM/s-1 were 
calculated using prism and were consistent to previously reported values. Inhibition 
assays were set up, however a model of inhibition could not be completely fitted to 
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Chapter Four - Biophysical Characterisation of VsDapL 
 
4.1  Introduction 
 
To assist X-ray crystallography and nuclear magnetic resonance structural studies, a 
range of biophysical techniques are available to probe the biological function of a 
protein 1, 2. These cover areas including hydrodynamics, thermodynamics and 
spectroscopy to uncover the properties of a protein in solution. As diaminopimelate 
aminotransferase (DapL) is a recently discovered enzyme, limited information is 
known about its structural characteristics, therefore biophysical techniques could aid 
the elucidation of its properties 3. In this chapter, the biophysical properties of 
Verrucomicrobium spinosum DapL (VsDapL) were explored using three techniques, 
circular dichroism spectroscopy (CD), analytical ultracentrifugation (AUC) and small 
angle X-ray scattering (SAXS). These techniques provide invaluable insight into the 
size, shape and structure of VsDapL in solution. 
 
4.2 Circular dichroism  
 
Circular dichroism spectroscopy is a biophysical technique that measures the 
difference in absorption of left-handed and right-handed circular polarised light 4. 
Peptide bonds of proteins absorb in the far-UV region of 180-240 nanometers (nm) 
and therefore CD is primarily used for the evaluation of the secondary structure 
composition, folding and binding properties of a protein 5, 6. α-Helices give a 
characteristic positive single peak at 193 nm and two negative peaks at 208 and 222 
nm on a CD spectrum, while β-sheets give a single positive peak at 195 nm and a 
single negative peak at 218 nm 5. The secondary structure elements of VsDapL were 
analysed using a wavelength-scan in the far-UV region (between 190-260 nm). The 
thermal denaturation of VsDapL was also measured using CD, however two other 
techniques, differential scanning calorimetry and differential scanning fluorimetry 
were used prior to analysis with CD. Both techniques gave inconclusive results and 







Figure 4.1  – Far-UV CD spectrum of VsDapL at 0.1 mg/mL in 50 mM Tris-HCl buffer, 150 mM 
NaCl  (pH 7.6) in a 2mm cuvette. The spectrum was collected between 190-260 nm and the mean 
residue ellipticity θ, was plotted against wavelength in nm.  
 
An initial wavelength scan between 190 and 260 nm resulted in a spectrum displayed 
two negative peaks at approximately 208 nm and 222 nm (Figure 4.1). These peaks 
indicate that VsDapL was folded in solution and contained a proportion of both α-
helices and β-sheets. 
 
A thermal denaturation profile for VsDapL was obtained at 220 nm by heating the 
sample from 20°C to 95°C and taking measurements at 0.3°C increments. The mean 
residue ellipticity θ was plotted as a function of temperature and is shown in (Figure 
4.2). The corresponding sigmoidal curve given denotes the thermal denaturation 
profile of VsDapL and by locating the midpoint of the transition, the melting 
temperature was calculated to be approximately 51°C. Wavelength scans were also 
taken at between 190 and 260 nm at 10°C increments to visualise the denaturation of 






Figure 4.2  – The thermal denaturation profile of VsDapL in 0.1 mg/mL in 50 mM Tris-HCl 
buffer, 150 mM NaCl  (pH 7.6) in a 2 mm cuvette.  Mean residue ellipticity [θ] at 220 nm is plotted 
against temperature and the thermal denaturation temperature is shown in red. 
 
 
Figure 4.3  – The overlay of the Far-UV CD spectra of VsDapL in 0.1 mg/mL in 50 mM Tris-HCl 
buffer, 150 mM NaCl  (pH 7.6) in a 2mm cuvette. Collected spectra were taken at 10°C increments 
between 190-260 nm and the mean residue ellipticity θ, was plotted against wavelength in nm. 






4.3 Analytical ultracentrifugation  
 
Analytical ultracentrifugation (AUC) is a powerful and versatile method for the 
quantitative characterisation of macromolecule associations in solution 7, 8. There are 
two experimental designs in AUC, sedimentation velocity, where the sedimentation 
process is the focus, and sedimentation equilibrium where the final equilibrium 
distribution is analysed 9, 10. Both techniques can provide useful information about 
thermodynamic and hydrodynamic properties of a macromolecule in solution. In this 
work, the sedimentation velocity experiment was used to assess the oligomeric state 
of VsDapL in solution. The experiment measures the rate at which molecules move in 
response to an applied centrifugal force, as a function of time, and therefore allows 
conclusions about its size and shape in solution 11, 12.  
 
As displayed in the three previously reported crystal structures, DapL adopts a homo-
dimeric structure (See chapter 1, section 1.4). It was reasoned that VsDapL should 
also adopt a dimeric oligomeric state, however to examine if there was a 
concentration dependence on the oligomeric state, VsDapL was tested at three 







Figure 4.4: Analytical ultracentrifugation sedimentation velocity of VsDapL carried out at three 
concentrations in 20 mM Tris-HCl, 150mM NaCl, pH 7.6 20ºC. (a) The sedimentation velocity of 
VsDapL at 0.3 mg/mL with the residuals for nonlinear least squares fit plotted. (b) The sedimentation 
velocity of VsDapL at 0.6 mg/mL with the residuals for nonlinear least squares fit plotted. (c) The 
sedimentation velocity of VsDapL at 0.9 mg/mL with the residuals for nonlinear least squares fit 
plotted. (d) An overlay of the continuous sedimentation coefficient c(s) distribution for all three 
concentrations plotted as a function of the sedimentation coefficient.  
 
Table 4.1: Calculated AUC parameters for VsDapL. 
 0.3 mg/mL 0.6 mg/mL 0.9 mg/mL 
Weight averaged c (s), S20,w 
RMSD 


















Sedimentation velocity data was fitted to a c(s) model and at the lowest concentration 
of 0.3 mg/mL, the c(s) plot displays peaks corresponding to sedimentation 
coefficients of approximately 4 and 6 S (Figure 4.4, d). The program, HydroPRO, was 
used to estimate the sedimentation coefficient for the dimeric structure of VsDapL 
from the molecular model (Chapter 5), and was calculated to be 5.73 S, consistent 
with the value of approximately 6 S given in the experiment. The lower 4 S peak 
corresponds to a monomer, and is shown to be at higher ratio than the 6 S peak, 
indicating that a higher proportion of monomer than dimer is present at this 
concentration. The quality of the nonlinear least squares best-fit is supported by the 
low root-mean-square deviation (RMSD) number of 0.006917 (Table 4.1), and the 
random residual distribution show normally distributed noise (Figure 4.4, a). The 
spike located on the residuals plot at just above 6.6 cm can be attributed to a scratch 
located on the cell that was used for the SV experiment at this concentration. 
 
At the concentration of 0.6 mg/mL the c(s) plot displays peaks corresponding to 
sedimentation coefficients of approximately 4 and 6 S (Figure 4.4, d). However, the 
c(s) peaks are different compared to the lower concentration indicating that the 
solution contains a higher proportion of dimer to monomer at this concentration. The 
quality of the nonlinear least squares best-fit is supported by the low RMSD number 
of 0.006672 and the random residual distribution show normally distributed noise 
(Table 4.1, b). 
 
At the final tested concentration of 0.9 mg/mL, the c(s) plot again displays two peaks 
at the same sedimentation coefficients as prior (Figure 4.4, d). The c(s) peak at around 
6 S is higher than that at 4 S and suggests that the dimeric species of VsDapL 
comprises the majority of the solution, however a small proportion of monomer is still 
apparent. The RMSD of 0.007286 (Table 4.1), and the random residual distribution 
showing normally distributed noise indicated the quality of the nonlinear least squares 
best-fit (Figure 4.4, c).  
 
The shift from a higher proportion of monomeric species at the lower concentrations, 
to a dimeric species at the higher concentrations examined here has not been reported 





dissociation constant (Kd) for VsDapL to between the ranges of 0.3 mg/mL-0.9 
mg/mL. 
 
4.4 Small angle X-ray scattering 
 
Following the previously unreported finding that the concentration of VsDapL could 
affect its oligomeric state in solution, the biophysical technique small angle X-ray 
scattering (SAXS) was used. SAXS is used for the structural characterisation of a 
protein in solution, and therefore can offer unique insight into functionally important 
conformational changes under physiologically relevant conditions 13. In this work, 
SAXS was used to complement the data obtained for VsDapL from AUC. 
 
SAXS data were collected at the Australian Synchrotron at SAXS/WAXS beamline 
and the scattering profiles were collected using the ATSAS package (Figure 4.5) 14. 
Parameters for SAXS data analysis are given in Table 4.2.  
 
The Rg against I(0) as a function of time plot shows that the Rg value (red) is stable 
across these I(0) values, indicating a monodisperse solution (Figure 4.5, a). The 
theoretical scattering profile from the dimeric crystal structure (chapter 5) is in close 
agreement with the experimental scattering model with a chi2 value of 0.142 given from 
SREFLEX 15 (Figure 4.5, b). The Guinier plot, overlaid on the scattering profile also 
indicates that the sample does not show any indication of aggregation or inter-particle 
interference. The bell shaped nature of the Kratky plot shows that the VsDapL is 
folded in solution (Figure 4.5, c). The maximum dimension of the particle (Dmax) 
calculated from the p(r) plot of 96 Å attained from SAXS, is in close agreement with 
96.1 Å measured for the dimeric crystal structure in Pymol, indicating that the 
enzyme is present as a dimer (Figure 4.5, d). AUC values for the dimeric molecular 







Figure 4.5: SEC-SAXS results for VsDapL. (a) Plots showing I(0) and Rg as a function of time for 
the SEC-SAXS run. (b) I(q) versus q. Theoretical scattering of VsDapL was fitted using SREFLEX. A 
















Table 4.2: SAXS structural parameters of VsDapL 
 VsDapL  









q range (Å-1) 
Porod volume (Å-3) 
Calculated molecular weight  
from Prorod volume (Da) 
- SAXS MoW analysis 
Molecular weight 




















In this chapter three techniques, each designed to ascertain aspects relating to 
different biophysical properties, were used to paint an overall picture of VsDapL in 
solution that could be used to complement X-ray crystallography studies. Circular 
dichroism spectroscopy was used as a tool to give insight into the secondary structure 
and thermodynamic properties of VsDapL. It was found that the protein backbone 
contains both α-helices and β-sheets and when heated, the melting temperature was 
calculated to be approximately 51°C. 
 
Analytical ultracentrifugation was used to investigate the oligomeric state of VsDapL 
in solution.  The identified feature of concentration dependent monomer-dimer 
equilibrium of VsDapL in solution was found. At lower concentrations a higher 
proportion of the monomeric species was present, but as the concentration increased a 
higher proportion of dimeric species were observed. This finding suggests that the 
dissociation constant (Kd) of the VsDapL monomer-dimer equilibrium to be in the 






Following AUC, Small angle X-ray scattering was used to investigate the size and 
shape of VsDapL. SAXS samples were folded in solution with no signs of 
interparticle interference or aggregation and displayed a maximum particle size of 96 
Å, consistent to what was found for a dimeric species in Pymol. The theoretical 
scattering profile calculated from the dimeric crystal structure of VsDapL was in close 
agreement with the experimental scattering profile and thus further supports the 
dimeric structure in solution at higher concentrations.  The biophysical data presented 
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 Chapter Five - The crystal structure of DapL from 
Verrucomicrobium spinosum 
 
5.1  Introduction 
 
X-ray crystallography is a powerful technique used to determine the atomic three-
dimensional structure of a protein or macromolecule 1. The atomic structure can be 
used to give detailed insights into the dynamics, interactions and function of a protein 
2, 3. In an effort to further characterise the diaminopimelate aminotransferase enzyme 
from Verrucomicrobium spinosum (VsDapL), X-ray crystallography was used to 
elucidate the crystal structure. As outlined in chapter one, the first published crystal 
structure of DapL was solved in from the plant A. thaliana and subsequent studies 
allowed the elucidation of DapL structures from the alga C. reinhardtii and the 
bacteria C. trachomatis 4-6.  
 
This chapter describes the first X-ray crystal structure of VsDapL. 
 
 5.2  Crystallisation and refinement.  
 
Previously reported methods used to crystallise DapL, were trialed for the 
crystallisation of VsDapL using the hanging drop-vapor diffusion method 4-6. Over 
3000 conditions were trialed, but after crystals failed to form subsequent changes of 
crystallisation conditions were made including the variation of buffers, pH range, salt 
concentrations, temperature, enzyme concentration and binding partners. Crystals of 
his-tagged VsDapL appeared in a condition (60 % v/v T-mate pH 7.0) after 2 months 
containing two inhibitors, malic acid and maleic acid (Figure 5.1). The crystals were 
delicate square sheets measuring 100 µm in their largest dimension. Crystals were 
harvested and soaked in cryo-protectant solution and flash-frozen in liquid nitrogen 
(chapter 6, section 6.8.4).  Crystals obtained in this condition diffracted to 2.25 Å and 
crystallised into the space group P21 with 2 chains present in the asymmetric unit. 
Diffraction data sets were processed using molecular replacement using Phaser 7, with 










Figure 5.1: Protein Crystals of VsDapL. (a) Crystals of VsDapL that formed in the presence of 
maleic acid (left) and malic acid (right). (b) The diffraction scattering pattern of the crystal that 









Table 5.1: Data collection and refinement statistics  




























Reflections used in refinement 










R.M.S Bonds (Å) 
R.M.S Angles (°)      





Ramachandran favoured  (%) 
Ramachandran allowed (%) 
Ramachandran outliers 










56.05, 121.37, 76.54 















































The final model contains 808/822 fitted amino acids and includes residues 1-68, 76-
411 in both A and B chains. Poor electron density was observed for residues between 
R68 and P76 of both monomer chains, a region shown to comprise a flexible mobile 
loop region in other structures. Electron density was also poor for residues between 
S250 and V258 on both chains. Residues in this region were found to be highly 
conserved and form the contacts for the dimer interface and also the active site 
pocket. 
 
5.3  General features of the VsDapL crystal structure 
  
The native VsDapL monomer contains 411, amino acids but is likely to form a dimer 
of 822 amino acids at higher concentrations (Chapter 4). The solved crystalline 
structure is in agreement with the findings in chapter 4 of a dimeric oligomeric state 








Figure 5.2: The solved crystal structure of VsDapL shown in Pymol 8. (a) The structure of VsDapL 
(green) overlaid with the dimeric structure of CrDapL (Red). (b) The homo-dimeric structure of 
VsDapL indicating both monomers. N- and C- termini are labeled in the corresponding colours. (c) The 
structure of VsDapL shown with the malate ion (red) bound in both active sites. The dimer is displayed 
in a surface space-filling model and is rotated 90° to outline one of the active sites binding pocket. 
Secondary structure analysis revealed that the protein backbone contains both α-
helices and β-sheets (chapter 4, section 4.2). This finding is supported this by the α/β 
type protein fold displayed in the crystal structure, however consistent with other 
reported structures, the backbone contains a higher content of α-helices. The overall 
protein fold of VsDapL resembles type I aminotransferases, and reaffirms the 






5.4  VsDapL monomer features   
 
Two chaliced-shaped monomers (A, B) are present in the asymmetric unit and are 
related by a non-crystallographic 2-fold axis and associate to form a homodimer, a 
typical feature of type I PLP-dependent aminotransferases 5. Each monomer is 
comprised of a N-terminus arm (residues M1-L50), a large domain (LD) (residues 
P51-G325) and a small domain (SD) (residues N366-K411) and fold together to form 
a α-β-α complex (Figure 5.3).  
 
Figure 5.3: The VsDapL monomer structure. (a) The three domains (LD, SD and arm regions) of the 
monomer and active site of VsDapL with the malate ion (red) and PLP (yellow) bound. (b) The 90° 
rotation of the monomeric active of VsDapL with the malate ion (red) and PLP (yellow) bound in the 






Protein sequence alignments and structural modeling of known DapL orthologues 
display that catalytic residues that comprise the active site stem from both monomers 
and are highly conserved, indicating that a dimeric oligomeric state is required for 
activity. 
 
5.5  Dimer interface analysis   
 
In solution, monomers A and B self-associate to form a homodimer. The dimeric 
interface contains two active sites located in an internal cavity of each monomer, 
consistent with the previously reported structures (Figure 5.4). PISA analysis of the 
VsDapL structure shows that it has a weak dimer interface consisting of 83 residues 
(20.5%) from monomer A and 81 residues (20.0%) from monomer B 10. 
Approximately 20% of the protein is solvent inaccessible as it is concealed in the 
interface, primarily held together with hydrogen bonds. Forming a homo-dimer from 
monomer A and B is enthalpically favorable as solvation gain is 14.5 kcal/mol, yet in 
solution the monomer and dimer associate very weakly with a Kd of between 0.3 and 
0.9 mg/mL (Chapter 4). 
 
 
Figure 5.4: A surface model of the VsDapL monomer displaying the residues in red that form the 





A multiple sequence alignment of DapL orthologues shows that the residues that form 
that the dimeric interface in VsDapL are not fully conserved in other orthologues. The 
discrepancy of conservation in these residues between organisms may explain the 
weak dimer interface that is seen in VsDapL. 
 
Figure 5.5: A multiple sequence alignment of VsDapL with the previously reported DapL 
orthologues. Red characters denote the residues involved in the dimeric interface. Green–highlighted 
areas denote motifs that are involved in active site formation. Blue-highlighted residues are the 
residues found to be involved in active site contacts. Symbols below the sequence alignment relate to 





5.6  VsDapL active site architecture 
 
Homology modeling and sequence alignment reveal that there are 10 highly 
conserved residues involved in substrate binding (Figure 5.5). In the VsDapL 
structure, 9/10 active site residues have been fitted. They are, I43, G44, K111 Y134, 
N189, K251 and R390 from one monomer and Y74*, E77* and N294* from the 
opposing monomer (Figure 5.6). As noted previously, the density for the residues 
between R68 and P76 on both chains was poor and therefore the residue Y74* could 
not be resolved in the VsDapL structure. However a position in the active site is 
available where the Y74* residue has been reported to be found (Figure 5.6). 
 
Figure 5.6: The active site architecture of VsDapL. Residues from the opposing monomer are 
coloured in blue and are signified with the * sign. A gap exists (shown in the bottom right of the figure) 






5.6.1  Malate Binding site 
 
VsDapL was crystallised in the presence of two previously identified inhibitors, malic 
acid (200mM) and maleic acid (100 mM) 6. At pH 7.6, both inhibitors form their 




Figure 5.7: The chemical structures of the malate and maleate ions. Adapted in CHEMDRAW 6. 
 
Electron density in the position where the malate/maleate ion has been reported to 
bind was reported in the VsDapL (Figure 5.8). The density more closely resembled 
the malate ion, over the maleate ion and therefore the malate ion was modeled into the 
crystal structure. The malate ion is shown to form interactions with nearby active site 
residues and is consistent with previously reported structures. A nearby water 
molecule located in the active site, has been shown to form an interaction with the 
malate ion in previous structures. However in the VsDapL structure, the water 
molecule does not form a contact with the malate ion suggesting that the malate ion 







Figure 5.8: The malate binding site of VsDapL. Malate is shown in yellow, residues from monomer 
A are shown in green and residues from monomer B are shown in blue. Residues are coloured by 
element and interactions are shown using orange dashed lines. 
 
5.6.2  PLP Binding site 
 
Located in close proximately to the malate ion in the active site, is the co-factor 
pyridoxal-5-phosphate. PLP is an essential part of the transaminase reaction and is 
covalently bound to the active site residue K251 through an imine linkage 11. The 
electron density for PLP in active site in VsDapL is in line with previous structural 
studies that have reported the position of PLP. PLP has been shown to form bonds 








Figure 5.9: The PLP binding site of VsDapL. PLP is shown in grey, residues from monomer A are 
shown in green and residues from monomer B are shown in blue. Residues are coloured by element 
and interactions are shown using orange dashed lines. 
 
However, when PLP is modeled in the VsDapL crystal structure with the malate ion 
present, the suggested position for forms fewer contacts with the conserved residues 
in the active site than in previously reported structures (Figure 5.10). The density for 
the PLP and the binding residues is ill defined, perhaps suggesting that this region is 






Figure 5.9: The PLP binding site of VsDapL with the malate ion present. PLP is shown in grey, 
residues from monomer A are shown in green and residues from monomer B are shown in blue. 




In this chapter, the first X-ray crystal structure of VsDapL was solved. This was done 
by co-crystallisation of VsDapL with the inhibitor malic acid/maleic acid. The crystals 
diffracted to 2.25 Å and the structure was solved using molecular replacement. Above 
95% of the residues were fitted to the electron density, however a region between R68 
and P76 could not be solved. An ill-defined region between serine S250 and V258 
that forms that active site binding pocket was fitted. The overall crystalline structure 





the enzyme in solution in chapter 4. The dimer is comprised of two monomers (A, B) 
and are related by a non-crystallographic 2-fold axis consistent with type I 
aminotransferases. A multiple sequence alignment shows that the dimeric interface 
residues are not highly conserved while active site residues are highly conserved 
between organisms The active site density reported for the co-crystallised substrates 
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The biosynthesis of L-lysine through the diaminopimelate pathway is an appealing 
target for the development of algaecides, herbicides and therapeutics, as the pathway 
is absent in animals but present in bacteria, plants and algae. One of the pathways 
within the Dap pathway catalysed by the enzyme diaminopimelate aminotransferase 
(DapL) had been characterised in three previous organisms, Arabidopsis thaliana, 
Chlamydomonas reinhardtii and Chlamydia trachomatis, however each organism can 
synthesise L-lysine through alternative routes. The bacterium Verrucomicrobium 
spinosum on the other hand, only synthesises L-lysine using DapL and as such was 
used as a model organism for the viability of this enzyme as a target.  Presented for 
the first time in this thesis is the kinetic, biophysical and structural characterisation of 
DapL V. spinosum. 
 
When elucidating the kinetic parameters of VsDapL, it was found that the enzyme is 
quite inefficient in respect to its substrate, L,L-Dap. The biophysical and structural 
studies may offer an explanation into why this is. Our biophysical studies show that in 
solution at concentrations at and below 0.3 mg/mL, VsDapL exists in a primarily 
monomeric state. However as the concentration increases, the proportion of 
monomeric species to dimeric species increases, demonstrating a monomer-dimer 
equilibrium. Previous studies structural for DapL show it to exist in a dimeric state 
with residues comprising the active site to come from both monomers, indicating that 
a dimeric oligomeric state is required for activity. This was consistent with what was 
found in the solved crystal structure for VsDapL as it resembled a typical type I 
aminotransferase enzyme.  As the attempted assays were at a low concentration of 
enzyme, it is likely that the species in solution was monomeric and thus full activity is 
not seen and resulted in the kinetic parameters given. The structural analysis of 
VsDapL also shows that residues that comprise the dimeric interface are not 
conserved between organisms and may contribute to why this monomer-dimer 
equilibrium is seen in VsDapL and is not in other organisms that use DapL. The 
monomer dimer-equilibrium may be a result of V. spinosum exclusively using the 
DapL pathway for L-lysine biosynthesis, however further studies are required to 





To summarise, presented in this work is the first kinetic, biophysical and structural 
characterisation of the enzyme diaminopimelate aminotransferase (DapL) from ta 


































Chapter Six - Methods and Materials 
 
6.1 Chemicals, materials and general equipment 
 
Unless stated otherwise, general reagents and chemicals that were purchased through 
Sigma-Aldrich, Applichem, Molecular dimensions and Hampton Research. 
 
All Eppendorf tubes and pipette tips were sterilised by autoclaving (121°C for 20 
minutes). 
 
All protein and DNA experimental work was conducted on ice or at 4°C. DNA and 
protein solutions were temporarily stored at 4°C unless otherwise stated. 
 
6.2   Stock solutions 
 
All buffers, reagents and solutions requiring H2O were prepared with Milli-Q H2O, 
and filtered with a 0.22 µm filter. 
 
Stock solutions of isopropyl β-d-1-thiogalactopyranoside (IPTG) were prepared with 
Milli-Q H2O, filtered with a 0.22 µm filter and stored at -20°C in aliquots. 
 
All prepared antibiotics were filtered with a 0.22 µm filter and stored at -20°C (Table 
6.1). 
  
Table 6.1: Antibiotic concentrations 




Kanamycin  30 30 












6.3  Molecular biology 
 
6.3.1  Bacterial work and strains 
 
All work with bacteria was completed using aseptic techniques, inside either a 
laminar flow cabinet or beside a flame. All equipment was sterilised by autoclaving. 
 
The pET-30a (+) plasmid (kanamycin resistance) encoding the gene for his-tagged 
Verrucomicrobium spinosum diaminopimelate aminotransferase (DapL) was 
generously supplied by the co-supervisor of this work, Associate Professor André O. 
Hudson of The Rochester Institute of Technology.  
6.3.2 Protein sequence  
 
Protein sequence of DapL from Verrucomicrobium spinosum (411 amino acids) 
obtained from the NCBI website. 
 
1  MALINENFLK LKAGYLFPEI ARRVKAFTEG NPEAAQRLIR 
CGIGDVTEAL PEAVRYAMHE         
61  AVDELGNRST FKGYGPEQGY DFLRNAIADN DYKARGLPIE 
ADEIFISDGS KCDTGNILDI        
121  FGQGNTIAIT DPVYPVYVDT NVMIGNTGEA DENGAYAGLV 
YLKCTPENGF VPDIPQEKAD        
181  LIYLCYPNNP TGAVATRPQL EAWVKYAREN GSVLLYDAAY 
EAFIQDPTIP HSIFEIEGAR        
241 DCAIEFRSFS KNGGFTGVRC AYVVIPKSLM GRKKNGEAQA 
LHPLWSRRHS TKFNGASYIV        
301  QKGAEALYTD EGKSQTKALI EHYMGNAALL VEACKNAGLS 
VFGGVNAPYV WVGCPAGLTS        









Luria-Bertani (LB) medium was prepared using 25 g of powder per 1 L of Milli-Q 
H2O and was autoclaved at 121°C for 20 minutes. 
 
6.3.4 Agar plates 
 
LB agar was prepared using a 5:3 ratio of LB powder to agar e.g. 25 g LB powder: 15 
g of agar per 1 L. Following autoclaving and cooling to 50°C, an appropriate 
antibiotic was added as a 1000x stock (section 6.2). Approximately 25 mL was then 
poured into each petri dish and left to solidify for 30 minutes in a laminar flow 
cabinet. 
 
6.3.5 Starter culture preparation 
 
Agar plates containing the appropriate antibiotic were streaked using a sterilised 
spreader or pipette tip with a glycerol stock (section 6.3.6). Positive and negative 
controls were prepared by streaking with chloramphenicol, ampicillin or no antibiotic.  
 
The plates were then incubated at 37°C overnight (14-16 hours). A colony was then 
picked using a sterile pipette tip and used to inoculate fresh LB media (5-200 mL) 
containing the appropriate antibiotic. The media was then incubated at 190 rpm and 
37°C overnight (14-16 hours). 
  
6.3.6 Glycerol stocks 
 
Glycerol stocks were set up by mixing 500 µL of the overnight starter culture with 
500 µL of 50% glycerol in 1.7 mL Eppendorf tube. The contents were mixed, snap 








6.3.7 Competent cell transformation 
 
Competent BL21(DE3)* Escherichia. coli cells were thawed on ice and added to a 
cold Eppendorf tube containing 2-3 µL (80-100 ng) of plasmid containing VsDapL. 
After mixing, the Eppendorf tube was incubated on ice for 30 minutes before being 
heat shocked in a heating block or water bath at 42°C for 60 seconds. Following the 
heat shock, the tube was placed adding 950 µL of Super Optimal Broth with 
catabolite repression (SOC) medium. The tube was then incubated at 37°C and 190 
rpm for 60 minutes. Following this, 100 µL of the solution was plated onto a 
kanamycin agar plate. Contamination was checked by plating 100 µL of culture onto 
three control agar plates. These plates were as follows: a positive control plate with no 
antibiotics, and two negative control plates containing chloramphenicol and 
ampicillin. All agar plates were incubated at 37°C overnight (14-16 hours). 
 
6.4  Protein Biochemistry 
 
The methods and protocols within this section were performed using aseptic 
technique when appropriate and all protein work was completed either at 4°C or on 
ice.  
 
6.4.1  Expression trials 
 
Expression trials for VsDapL were conducted using small-scale cultures of LB to find 
optimum expression condition. Glycerol stocks were streaked onto agar plates 
containing appropriate antibiotics. A single colony was picked using a sterilised 
pipette tip and added to 5-20 mL of LB with kanamycin. This culture was incubated 
overnight at 190 rpm and 37°C. Larger autoclaved cultures (20-100mL) containing 
kanamycin were inoculated using 5 mL of the overnight culture and incubated at 190 
rpm and 37°C to an optical density at 600 nm (OD600) of 0.4-0.6. Protein expression 
was then induced by adding 1 M IPTG to a final concentration of 1 mM. The culture 





6.4.2 Testing for overexpression 
 
Samples at different stages during the induction were taken for overexpression 
testing. Samples were taken at pre-induction, 2 hours; 6 hours and 14 hours post 
induction. Samples were analysed by SDS-PAGE for over-expression of VsDapL 
(Section 6.4.4).  
 
6.4.3  Full scale protein expression 
 
Protein expression followed the same protocol as described in section 7.4.1 with 
slight modifications. Overnight cultures were used to inoculate 1 L cultures that were 
induced with 1 M IPTG to a final concentration of 1 mM. Following overnight 
induction, the cells were harvested by centrifugation at 8,000 x g for 15 minutes at 
4°C. The supernatant was discarded and cell pellets were either put on ice for 
immediate purification or transferred into 50 mL falcons tubes and stored at -20°C. 
 
6.4.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
visualise the purity of protein. Bolt® Pre-cast 4-12% Bis-Tris Plus 10 well or 15 well 
electrophoresis gels were supplied by Novex (Novex® by Life Technologies™). 
MES SDS 1x stock was used as the running solution for electrophoresis. Novex® 
Protein size estimation in kilo Daltons (kDa) was determined by loading 7 µL of 
Sharp Pre-Stained Protein Standard (Novex® by Life Technologies™) into one of the 
wells of the gel. Each used well contained 10 µL of protein sample, 16 µL of filtered 
Milli-Q H2O, 10 µL of Bolt™ LDS Sample buffer 4x and 10 µL of reducing agent 
(Dithiothreitol (DTT) or Tris (2carboxyethyl) phosphine (TCEP) 10 mM). Samples 
were then heated to 80°C in a heating block for 10 minutes before loading 10 µL into 
appropriate wells of the gel (Table 6.2).  
The gels were run at 165 V for 35 minutes and stained for 30 minutes using 
Coomassie brilliant blue stain. Coomassie blue was prepared by adding 1 g 





Gels were destained using Coomassie destain (450 mL methanol, 450 mL water, 100 
mL acetic acid) until the gel was de-stained sufficiently. Gels photos were imaged 
using a bio 5000 + microter scanner. 
 
Table 6.2: SDS-PAGE sample components 
Reagents Reason Volume (µL) 
Milli-Q H2O To make up volume 16 












6.4.5 Cell lysis 
 
Cell pellets were thawed on ice and fully re-suspended in 20-30 mL IMAC binding 
buffer 1 (Table 6.3), then lysed by sonication for 12 minutes at 70% frequency and 
0.5 second interval. Following lysis, the solution was centrifuged at 13,000 x g at 4°C 
for 15 minutes. The supernatant (crude lysate) was carefully collected, transferred to a 
sterile 50 mL Falcon tube and kept on ice. 
 
Table 6.3: Expression and purification buffers. 
Buffers Buffer Solution 
IMAC Buffer 1 Non-Specific Binding 50 mM sodium phosphate, 300 mM 
NaCl, 40 mM Imidazole, pH 8.0. 






Size Exclusion buffer 1 (SEC) 
Size Exclusion buffer 2 (SEC) 
 
Size Exclusion buffer 3 (SEC) 
50 mM Sodium Phosphate, 300 
mM NaCl, 250 mM Imidazole, pH 
8.0. 
50 mM Sodium Phosphate, 300 
mM NaCl, 40 mM Imidazole, 0.3 
mg/mL Enterokinase pH 8.0. 
20 mM Tris, 150 mM NaCl, pH 7.6. 
100 mM HEPES-KOH, 1 mM 
DTT, 2 mM EDTA, pH 7.6. 
20 mM HEPES-KOH, 100 mM 





6.5 Protein purification 
 
6.5.1 Immobilised metal affinity chromatography (IMAC)  
 
Immobilised metal affinity chromatography (IMAC) was used as the first purification 
step. The 5 mL IMAC column (GE healthcare) was first equilibrated by running 
through 25 mL of Milli-Q H2O followed by 15 mL of IMAC buffer 2 containing high 
imidazole to prime the column. As the final equilibration step, 15 mL of IMAC buffer 
1 containing low imidazole was run through the. The crude lysate was then loaded 
onto the column and washed with 25 mL of IMAC buffer 1. The flow through was 
collected and run back through the column to ensure maximum binding of protein to 
the column. The protein was then eluted with 10 mL of IMAC buffer 2 containing 
high imidazole and collected in 0.5 mL fractions. These fractions were tested using 
SDS-PAGE (section 6.4.4) and fractions containing protein of interest were pooled. A 
sample was taken to estimate protein concentration using the A280 Nanodrop or the 
Bradford assay (section 6.5.4) 
6.5.2 His-tag cleavage  
 
A semi permeable dialysis membrane was knotted at one end and loaded with a 2mL 
of his-tagged VsDapL. The other end was then tied and both ends were clipped before 
being submerged in 2 L of dialysis buffer containing enterokinase (Table 6.3). This 
was then placed on a magnetic stirrer at 4°C and left to equilibrate for 24 hours. After 
24 hours the tubing was cut open and the protein solution was carefully removed. This 
solution was loaded onto the his-Trap column, washed with 5 mL IMAC buffer 1 
(Table 6.3) and the flow through was collected. 
 
6.5.3 Buffer exchange 
 
Pooled fractions containing VsDapL were added to a 30 kDa MWCO spin 
concentrator (Sartorius), and concentrated down to 2 mL by centrifugation at 7000 





using a pipette to prevent aggregation. The spin concentrator was refilled a minimum 
of three times to 20 mL using the desired buffer and centrifuged down to a final 
volume of 1.5 mL. 
 
6.5.4 Size exclusion column chromatography (SEC) 
  
Size exclusion chromatography (SEC) was used in the two-step purification of 
VsDapL to separate proteins that may have co-eluted with VsDapL during IMAC 
purification. A pre-packed 120 mL Superdex 200 gel filtration column (GE 
Healthcare was equilibrated with 500 mL of desired SEC buffer (Table 6.3). VsDapL 
was concentrated to 1.5 mL injected onto the column and run with 120 mL of 
equilibrated buffer at 0.3 mL per minute. Fractions were collected in a 96 well plates 
and analysed by SDS-PAGE. Following SDS-PAGE fractions containing pure 
VsDapL were pooled and concentrated using a 30 kDa MWCO spin concentrator 
(Sartorius), before being aliquotted into different volumes, snap frozen in liquid 
nitrogen and stored at -80 °C 
 
6.5.5  Protein concentration determination  
 
Most protein concentration measurements were determined using a Nanodrop ND-
1000 spectrophotometer at 280 nm. Protein concentration was calculated using the 
extinction coefficients at 280 nm (52300, 1.69 g/L), calculated from the amino acid 
sequence using exPASy ProtParam and beer’s law 1. The Bradford assay was also 
used as another method for determining the concentration of protein samples 2. The 
spectrophotometer was blanked using 800 µL Milli-Q H2O and 200 µL Bio-Rad Dye. 
Samples were mixed and left for at least 5 minutes at room temperature before being 
read at 595 nm. Protein concentrations were calculated using a calibration curve from 








Table 6.4: Components of the Bradford assay 
Reagents Volume (µL) 










All kinetics measurements were performed in triplicate. Buffer and reagent solutions 
used in the assays were filtered using a 0.22 µm filter when appropriate and either 
kept on ice or at 4°C. Serial dilutions were used to achieve desired concentrations of 
reagent and protein solutions. Protein concentration was confirmed using the 
Nanodrop A280. Activity and inhibition of VsDapL were measured using an adapted 
version of the ortho-aminobenzaldehyde assay 3, 4. All assays were performed in 
triplicate at 30°C over 200 minutes. 
 
6.6.1 The o-Aminobenzaldehyde assay 
 
VsDapL was thawed from 80°C on ice and centrifuged at 14,000 x g and 4°C for 15 
minutes before use. Appropriate concentrations were then made up using serial 
dilutions in the desired buffer. All reagents (Table 6.5) were added to a 1.7 mL 
Eppendorf tube and incubated at 30°C for 15 minutes before being transferred into a 1 
mL cuvette. The spectrophotometer was blanked against buffer during this incubation 
period.  The cuvette was then placed in the spectrophotometer followed by the 
addition of 50 µL of buffer. As the last step for all assays, 100 µL of VsDapL at the 
desired concentration for the assay was added, bringing the final volume to 1 mL. The 
contents of the cuvette were thoroughly mixed using a pipette and the absorbance was 
tracked at 440 nm over 200 minutes. Controls containing no substrate in the presence 












L,L-DAP 50 mM 2.3 mM 39.1 
α-Ketoglutarate (2OG) 
o-aminobenzaldehyde  



















6.6.2 The o-Aminobenzaldehyde inhibition assay  
 
A stock solution (200mM) of the inhibitor, malic acid, was prepared in Milli-Q H2O 
and adjusted to pH 7.0 with NaOH. The o-aminobenzaldehyde assay was then set up 
as per section 6.6.1 (Table 6.6). Desired concentrations of the inhibitor were added to 
the 1.7 mL eppendorf tubes to a final volume of 850 µL and incubated at 30°C for 15 
minutes before being transferred into a 1 mL cuvette. The cuvette was then placed in 
the spectrophotometer followed by the addition of 50 uL of buffer. As the last step, 
100 µL of VsDapL at the desired concentration for the assay was added, bringing the 
final volume to 1 mL. An additional control was also set up containing substrate and 
enzyme but no inhibitor. The absorbance was monitored at 440 nm over 200 minutes. 
 
Table 6.6: The o-aminobenzaldehyde assay reagents. Both the malic acid and buffer volumes 




































6.6.3 Kinetic data analysis  
 
The data collected from the assays was analysed the GraphPad Prism 6 software. The 
kinetic parameters KM and Vmax were found by plotting the substrate concentration the 
maximum velocity at 440 nm. Inhibitor parameters including KI were found by 
plotting the concentration of inhibitor against the maximum absorbance at various 
substrate concentrations at 440nm.  
 
6.7  Biophysical Techniques 
 
6.7.1 Far-UV circular dichroism spectroscopy  
 
6.7.1.1  Buffers and sample preparation 
 
Purified VsDapL stored in 20 mM Tris-HCl, 150 mM NaCl at pH 7.6 was thawed on 
ice and centrifuged at 14,000 x g for 15 minutes at 4°C. It was then diluted to 1 
mg/mL in the same buffer followed by a further dilution in Milli-Q H2O to give a 
final concentration of 0.01 mg/mL. Then buffer was diluted by the same amount in 
dilution in Milli-Q H2O for a reference blank. 
6.7.1.2  Wavelength scans 
 
The buffer blank was loaded into a Jasco J-815 circular dichroism (CD) spectrometer 
in a 2 mm path length quartz cuvette and a reading was taken. The cuvette was 
carefully cleaned and loaded with sample, and a far-UV spectra was taken between 
190 and 260 nm at 20°C. The reported spectra were the average of three scans that 








6.7.1.3 Temperature/wavelength thermal melt scans 
 
VsDapL was diluted to 0.05 mg/mL as per section 6.7.1.1 and loaded into a 10 mm 
path length cuvette. The instrument was blanked with buffer then loaded with the 
sample and an initial scan was taken between 190-260 nm. Thermal denaturation was 
monitored by recording the ellipticity at 220 nm with data collected at 0.3 intervals 
between 25°C and 95°C. Three wavelength scans were also taken every 10°C and 
averaged. 
 
6.7.2 Analytical ultracentrifugation 
 
6.7.2.1  Sample preparation 
 
Purified VsDapL stored in 20 mM Tris-HCl, 150 mM NaCl at pH 7.6 was thawed on 
ice and centrifuged at 14,000 x g for 15 minutes at 4°C. Concentrations of of 0.3, 0.6 
and 0.9 mg/mL were obtained by serial dilutions in the same buffer and confirmed by 
Nanodrop at A280. 
 
6.7.2.2 Sedimentation velocity 
 
Analytical ultracentrifugation (AUC) sedimentation velocity experiments were 
performed at 30°C in a Beckman Coulter XL-I analytical ultracentrifuge using double 
sector quartz cells in an 8-hole AN-50 TI rotor. Data was obtained at 50,000 rpm 
using 380 µL of protein at 0.3, 0.6 and 0.9 mg/mL. Scans were taken at 280 nm and 
data was collected using absorbance optics. 
 
6.7.2.3 Data Analysis 
 
The program SEDNTERP was used to calculate buffer density and viscosity and an 





to fit experimental data to a continuous sedimentation coefficient c(s) model 6. The 
program, WinHydroPRO was used to estimate the sedimentation coefficient for the 
dimer of VsDapL from the molecular model 7 . 
 
6.7.3  Small angle X-ray scattering 
 
 
Small angle X-ray scattering (SAXS) data for VsDapL was collected on the 
SAXS/WAXS beamline equipped with a Pilatus 1 M detector (170 mm x 170 mm, 
effective pixel size 172 x172 µm) at the Australian Synchrotron. The wavelength of 
the X-rays was 1.0332 Å. The sample detector distance was 2400 mm, providing a q 
range of 0.01-0.3 Å−1.  VsDapL at 10 mg/mL was injected onto an inline Superdex 
S200 5/150 Increase (GE Healthcare), equilibrated with 20 mM Tris-HCl, 150 mM 
NaCl at pH 7.6 and supplemented with the radical scavengers 5 % (v/v) glycerol and 
0.1 % (w/v) sodium azide, using a flow rate of 0.45 mL/minute. Coflow SAXS was 
used to minimize sample dilution and maximise signal to noise. Scattering data was 
collected in 2-second exposures over the course of the elution using a 1.5 mm glass 
capillary at 285 K (12°C).  
 
6.7.3.3  Data analysis 
 
Data analysis was performed using the ATSAS 2.7 Package 8.  Guinier fits were 
performed using PRIMUS 9. Indirect Fourier transforms to give P(r) was calculated 
using GNOM 10. Theoretical SAXS scattering curves of the VsDapL crystal structure 
was generated from atomic coordinates and compared with the experimentally 











6.8  X-ray crystallography 
 
6.8.1  Initial crystallisation trials  
 
Purified VsDapL was concentrated to 10, 20 and 39 mg/mL in three different buffers 
(Table 6.3). Screening against possible crystallisation conditions in the three buffers 
was conducted using a range of screens (Molecular Dimensions Ltd) (Table 6.7). A 
multichannel pipette was used to transfer 35 µL of each condition from the screen into 
96 well plates. The plates were loaded onto a TTP Labtech mosquito® crystal robot 
and 200 nL of protein was mixed via a robot with 200 nL of each condition giving a 
final volume of 400 nL in each drop. The 96 well plates were then stored at either 8°C 
or 20°C. 
 
6.8.2 Co-crystallisation crystal trials  
 
Co-crystallisation of VsDapL was attempted following the protocol described in 
section 6.8.1, but prior to the mosquito crystal robot use the protein was mixed at a 
1:1 ratio with one of three binding partners (malic acid 200 mM, maleic acid 200 mM 
and L,L Dap 20 mM). The plates were loaded onto the mosquito crystal robot and 200 
nL of protein/inhibitor solution was mixed with 200 nL of each condition for a final 
volume of 400 nL in each drop. The 96 well plates were then stored at either 8 °C or 
20 °C. 
Table 6.7: Trailed crystallisation screens.  
Crystal screens (Molecular Dimensions Ltd) Crystal hits condition 
SG1 Screen HT-96 Well G5 (with malic and maleic acid) 
Structure Screen 1 + 2 
LMB Crystallisation screen 
Morpheus  













6.8.4 Experimental  
  
Crystals were harvested with a litho-loop and soaked in a cryo protectant solution 
containing 85% of crystallisation solution (SG1 Screen HT-96, well G5) and 15% of a 
master solution (50% glycerol and 50 % ethylene glycol) before being flash-cooled in 
liquid nitrogen. Diffraction data was collected at 110K on the MX2 beamline at the 
Australian Synchrotron at a wavelength of 0.9537 Å.  
 
6.8.5 Data analysis and structure determination 
 
 
Diffraction images were indexed and integrated using iMOSFLM 12. Scaling and data 
reduction was performed using SCALA from the CCP4 Program suite 13. Molecular 
replacement was performed using MolRep using the crystal structure of CrDapL 
(PDB: 3QGU) as the search model 14. The structure was refined using REFMAC 15 
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